🚀 VC round data is live in beta, check it out!
TaiMed Biologics Valuation Multiples
Discover revenue and EBITDA valuation multiples for TaiMed Biologics and similar public comparables like Avacta Group, Assembly Biosciences, Atea Pharmaceuticals, Century Therapeutics and more.
TaiMed Biologics Overview
About TaiMed Biologics
TaiMed Biologics Inc is a biotechnology company committed to have the expertise and capability in developing, manufacturing and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 (TMB-365 and TMB-380 combination), and Antibody-Drug Conjugates, ADCs.
Founded
2007
HQ
Employees
83
Website
Sectors
Financials (LTM)
EV
$421M
TaiMed Biologics Financials
TaiMed Biologics reported last 12-month revenue of $20M.
In the same LTM period, TaiMed Biologics generated had net loss of ($3M).
Revenue (LTM)
TaiMed Biologics P&L
In the most recent fiscal year, TaiMed Biologics reported revenue of $19M and EBITDA of ($109K).
TaiMed Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $20M | XXX | $19M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $8M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 42% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($109K) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1%) | XXX | XXX | XXX |
| EBIT Margin | (22%) | XXX | (23%) | XXX | XXX | XXX |
| Net Profit | ($3M) | XXX | ($4M) | XXX | XXX | XXX |
| Net Margin | (17%) | XXX | (19%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
TaiMed Biologics Stock Performance
TaiMed Biologics has current market cap of $461M, and enterprise value of $421M.
Market Cap Evolution
TaiMed Biologics' stock price is $1.69.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $421M | $461M | -0.1% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTaiMed Biologics Valuation Multiples
TaiMed Biologics trades at 21.2x EV/Revenue multiple, and (3846.0x) EV/EBITDA.
EV / Revenue (LTM)
TaiMed Biologics Financial Valuation Multiples
As of April 18, 2026, TaiMed Biologics has market cap of $461M and EV of $421M.
Equity research analysts estimate TaiMed Biologics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TaiMed Biologics has a P/E ratio of (135.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $461M | XXX | $461M | XXX | XXX | XXX |
| EV (current) | $421M | XXX | $421M | XXX | XXX | XXX |
| EV/Revenue | 21.2x | XXX | 21.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (3846.0x) | XXX | XXX | XXX |
| EV/EBIT | (97.7x) | XXX | (95.9x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 51.2x | XXX | XXX | XXX |
| P/E | (135.7x) | XXX | (122.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 78.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified TaiMed Biologics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
TaiMed Biologics Margins & Growth Rates
TaiMed Biologics' revenue in the last 12 month grew by 9%.
TaiMed Biologics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
TaiMed Biologics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (90%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 8% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 62% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 74% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
TaiMed Biologics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| TaiMed Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Avacta Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Assembly Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Atea Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Century Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Candel Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TaiMed Biologics M&A Activity
TaiMed Biologics acquired XXX companies to date.
Last acquisition by TaiMed Biologics was on XXXXXXXX, XXXXX. TaiMed Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by TaiMed Biologics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTaiMed Biologics Investment Activity
TaiMed Biologics invested in XXX companies to date.
TaiMed Biologics made its latest investment on XXXXXXXX, XXXXX. TaiMed Biologics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by TaiMed Biologics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout TaiMed Biologics
| When was TaiMed Biologics founded? | TaiMed Biologics was founded in 2007. |
| Where is TaiMed Biologics headquartered? | TaiMed Biologics is headquartered in Taiwan. |
| How many employees does TaiMed Biologics have? | As of today, TaiMed Biologics has over 83 employees. |
| Is TaiMed Biologics publicly listed? | Yes, TaiMed Biologics is a public company listed on Taipei Exchange. |
| What is the stock symbol of TaiMed Biologics? | TaiMed Biologics trades under 4147 ticker. |
| When did TaiMed Biologics go public? | TaiMed Biologics went public in 2010. |
| Who are competitors of TaiMed Biologics? | TaiMed Biologics main competitors are Avacta Group, Assembly Biosciences, Atea Pharmaceuticals, Century Therapeutics. |
| What is the current market cap of TaiMed Biologics? | TaiMed Biologics' current market cap is $461M. |
| What is the current revenue of TaiMed Biologics? | TaiMed Biologics' last 12 months revenue is $20M. |
| What is the current revenue growth of TaiMed Biologics? | TaiMed Biologics revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of TaiMed Biologics? | Current revenue multiple of TaiMed Biologics is 21.2x. |
| Is TaiMed Biologics profitable? | No, TaiMed Biologics is not profitable. |
| What is the current net income of TaiMed Biologics? | TaiMed Biologics' last 12 months net income is ($3M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.